New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 7, 2012
09:08 EDTAMRN, BAGL, HWD, AET, ABMD, SWHCOn The Fly: Pre-market Movers
HIGHER AFTER EARNINGS: Smith & Wesson (SWHC), up 3.9%... ALSO HIGHER: Einstein Noah (BAGL), up 8.9% after declaring $4.00 special dividend... Aetna (AET), up 1.2% after JPMorgan upgrades to Overweight... LOWER AFTER EARNINGS: Harry Winston (HWD), down 2.9%... ALSO LOWER: Amarin (AMRN), down 19.1% after announcing non-equity financing, saying continues to assess strategic alternatives... ABIOMED (ABMD), down 5.8% after an FDA panel voted to retain Class III status for certain pumps, including its Impella.
News For AET;BAGL;SWHC;HWD;AMRN;ABMD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 31, 2015
09:11 EDTAMRNEuropean Society of Cardiology
Subscribe for More Information
August 28, 2015
12:50 EDTSWHCOn The Fly: Top stock stories at midday
Subscribe for More Information
11:38 EDTSWHCSmith & Wesson rallies after beating Q2 estimates, raising FY16 guidance
Subscribe for More Information
09:23 EDTSWHCOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Big Lots (BIG), up 11.1%... Smith & Wesson (SWHC), up 4.8%... Splunk (SPLK), up 3%... Freeport-McMoRan (FCX), up 14.3% after Carl Icahn reported a 8.46% stake in the company... United Continental (UAL), up 5.8% after being added to S&P 500... Activision Blizzard (ATVI), up 5.8% after being added to S&P 500... DOWN AFTER EARNINGS: Violin Memory (VMEM), down 23.9%... bebe stores (BEBE), down 19.8%... Autodesk (ADSK), down 4.2%... Aeropostale (ARO), down 4%. ALSO LOWER: Peabody Energy (BTU), down 6.6% after Moody's downgraded the company to Caa1.
08:41 EDTSWHCSmith & Wesson reported 'very strong' Q1 results, says RBC Capital
Subscribe for More Information
August 27, 2015
18:52 EDTSWHCOn The Fly: After Hours Movers
Subscribe for More Information
16:19 EDTSWHCSmith & Wesson up 5% after reporting Q1 results, raising FY15 guidance
16:19 EDTSWHCSmith & Wesson raises FY16 EPS view to $1.14-$1.19 from $1.02-$1.07
Subscribe for More Information
16:16 EDTSWHCSmith & Wesson sees Q2 EPS 19c-21c, consensus 15c
Sees Q2 revenue $135M-$140M, consensus $129.58M.
16:13 EDTSWHCSmith & Wesson reports Q1 adjusted EPS 32c, consensus 22c
Subscribe for More Information
August 26, 2015
12:02 EDTAETAetna, MemorialCare announce accountable care collaboration in California
Subscribe for More Information
07:57 EDTSWHCSmith & Wesson volatility elevated into Q1 and outlook
Smith & Wesson September call option implied volatility is at 57, October is at 46, January is at 49; compared to its 52-week range of 26 to 61, suggesting large near term price movement into the expected release of Q1 results on August 27.
August 18, 2015
10:00 EDTABMDOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Abercrombie & Fitch (ANF) initiated with an Underperform at Wolfe Research... Abiomed (ABMD) initiated with a Buy at CRT Capital... Aeropostale (ARO) initiated with a Peer Perform at Wolfe Research... American Eagle (AEO) initiated with an Outperform, Top Pick at Wolfe Research... American Electric (AEP) initiated with a Buy at Mizuho... Benefitfocus (BNFT) initiated with an Overweight at First Analysis... Blue Buffalo Pet Products (BUFF) initiated with an Equal Weight at Morgan Stanley... Capitala Finance (CPTA) initiated with an Equal Weight at Stephens... Chico's (CHS) initiated with a Peer Perform at Wolfe Research... Children's Place (PLCE) initiated with an Outperform at Wolfe Research... Chimerix (CMRX) initiated with an Outperform at FBR Capital... Ciena (CIEN) initiated with a Market Perform at Northland... Crane (CR) initiated with an Outperform at William Blair... Entergy (ETR) initiated with a Neutral at Mizuho... Express (EXPR) initiated with an Outperform, Top Pick at Wolfe Research... Finisar (FNSR) initiated with a Market Perform at Northland... Francesca's (FRAN) initiated with a Peer Perform at Wolfe Research... Gap (GPS) initiated with an Underperform at Wolfe Research... Infinera (INFN) initiated with an Outperform at Northland... International Game (IGT) initiated with a Buy at Union Gaming... Juno Therapeutics (JUNO) initiated with an Outperform at FBR Capital... L Brands (LB) initiated with a Peer Perform at Wolfe Research... Luca Technologies (LUCA) initiated with an Outperform at Northland... Lumentum (LITE) initiated with an Outperform at Northland... M/A-COM (MTSI) reinstated with a Buy at Jefferies... MRV Communications (MRVC) initiated with an Outperform at Northland... Michael Kors (KORS) initiated with a Peer Perform at Wolfe Research... NN, Inc. (NNBR) initiated with a Buy at Stifel... NeoPhotonics (NPTN) initiated with an Outperform at Northland... Oclaro (OCLR) initiated with an Outperform at Northland... Scientific Games (SGMS) initiated with a Buy at Sterne Agee CRT... SolarCity (SCTY) initiated with a Neutral at UBS... Summit Materials (SUM) initiated with a Neutral at Citi... Tech Data (TECD) initiated with an Underperform at BofA/Merrill... Urban Outfitters (URBN) initiated with a Peer Perform at Wolfe Research... Zumiez (ZUMZ) initiated with an Underperform at Wolfe Research... lululemon (LULU) initiated with a Peer Perform at Wolfe Research.
August 17, 2015
16:11 EDTABMDAbiomed initiated with a Buy at CRT Capital
Subscribe for More Information
08:14 EDTABMDAbiomed announces FDA submission of Impella 2.5, Impella CP, Impella 5.0/LD PMA
Abiomed announced that it has submitted FDA pre-market approval, or PMA, supplemental submissions requesting to expand Impella 2.5 PMA approval to all of the Impella family of devices; Impella 2.5, Impella CP and Impella 5.0/LD. The submissions are for a set of indications related to the use of the Impella devices in patients suffering cardiogenic shock following acute myocardial infarction or cardiac surgery. A request for a longer duration of support is also included. These submissions are proposed as a supplement to the Impella 2.5 PMA approval for high risk percutaneous coronary intervention, or PCI, received on March 23, 2015, and include analysis on 415 patients from the FDA study RECOVER 1 and the U.S. Impella registry, and a relevant Impella literature review that references 692 patients in 17 clinical studies. Additionally, over 24,000 Impella patients supported by Impella devices were reviewed in a safety analysis provided using the FDA/Medical Device Reporting database. Through its review of the supplemental submission, the FDA will ultimately render a decision concerning the safety and efficacy of the Impella CP and the Impella 5.0 in the applied-for patient populations.
05:59 EDTAETStocks with implied volatility movement; AET PMCS
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use